Ardelyx does ‘not agree’ with FDA’s view after agency rejects blockbuster prospect—and one analyst is ‘flummoxed’news2021-07-30T13:31:02+00:00July 30th, 2021|Fierce Pharma|
Intercept charts new path to NASH approval for obeticholic acid, as long as safety holdsnews2021-07-30T11:39:34+00:00July 30th, 2021|Fierce Pharma|
Fierce Pharma Asia—AstraZeneca’s China growth; Takeda’s $3.5B neuro pact; Biocon, Viatris’ historic biosimilar nodnews2021-07-30T09:35:25+00:00July 30th, 2021|Fierce Pharma|
As Veklury’s sales slide, Gilead hopes for a quicker rebound from Biktarvy, other HIV drugsnews2021-07-30T05:33:20+00:00July 30th, 2021|Fierce Pharma|
Innovation director puts new title to the test with virtual reality glasses and 3-D cities in pharma marketingnews2021-07-29T23:25:50+00:00July 29th, 2021|Fierce Pharma|
GlaxoSmithKline’s Nucala beats AZ’s Fasenra to the IL-5 punch in nasal polypsnews2021-07-29T20:46:58+00:00July 29th, 2021|Fierce Pharma|
U.S. sent Mexico and Canada AstraZeneca COVID-19 vaccines before fully vetting production site: reportnews2021-07-29T20:26:10+00:00July 29th, 2021|Fierce Pharma|
BioMarin gears up for two ‘transformational’ launches, Voxzogo and Roctavian: CEOnews2021-07-29T20:15:11+00:00July 29th, 2021|Fierce Pharma|
How well will Biogen’s Alzheimer’s drug Aduhelm perform in the real world? This study is set to find outnews2021-07-29T15:28:08+00:00July 29th, 2021|Fierce Pharma|
Emergent wins FDA all-clear to restart J&J COVID-19 vaccine production in Baltimorenews2021-07-29T15:26:40+00:00July 29th, 2021|Fierce Pharma|
